Enhanced TDS
Knowde-enriched technical product data sheet
Identification & Functionality
- Chemical Family
- Polymer Name
- Plastics & Elastomers Functions
- Technologies
- Product Families
Features & Benefits
- Labeling Claims
- Materials Features
Applications & Uses
- Markets
- Applications
- Plastics & Elastomers End Uses
- Plastics & Elastomers Processing Methods
- Applications
- Thin wall packaging
- Food containers
- Cosmetic containers
- Aerosol dust covers
- Processing Conditions
Typical processing conditions Injection Molding Zone 1 (°C) 180 - 200 Zone 2 (°C) 200 - 220 Zone 3 (°C) 210 - 230 Zone 4 (°C) 225 Nozzle (°C) 215 - Safripol Medical Application Policy
Safripol will not knowingly sell or sample any product or service (“Product”) into any commercial or developmental application that is intended for:
a. permanent (Long term) contact with internal body fluids or internal body tissues. Long term is a use which exceeds 72 continuous hours.
b. use in cardiac prosthetic devices regardless of the length of time involved; (Cardiac prosthetic devices include, but are not limited to, pacemaker leads and devices, artificial hearts, heart valves, intra-aortic balloons and control systems, and ventricular bypass assisted devices);
c. use as a critical component in medical devices that support or sustain human life; or
d. use specifically by pregnant women or in applications designed specifically to promote or interfere with human reproduction.
Additionally, all Products intended for use in pharmaceutical applications, other than pharmaceutical packaging, must pass the current Pharmaceutical Liability Guidelines.
● New business opportunities require a business assessment prior to sale or sampling of Safripol products.
● Authorized distributors and resellers will adhere to this medical policy.
● Safripol does not endorse or claim suitability of their products for specific medical applications. It is the responsibility of the medical device or pharmaceutical manufacturer to determine that the Safripol product is safe, lawful, and technically suitable for the intended use.
SAFRIPOL MAKES NO WARRANTIES, EXPRESS OR IMPLIED, CONCERNING THE SUITABILITY OF ANY SAFRIPOL PRODUCT FOR USE IN MEDICAL APPLICATIONS.
Properties
- Physical Properties
Value Units Test Method / Conditions Melt Flow Rate (230 °C/ 2.16 kg) 40 g/10min ISO 1133 Density 0.902 g/cm3 ISO 1183 - Mechanical Properties
Value Units Test Method / Conditions Tensile Strength at Yield 28 MPa ISO 527 Elongation at Yield 11 % ISO 527 Flexural Modulus 1000 MPa ISO 178 Charpy Notched Impact Strength (23 °C) 5 kJ/m2 ISO 179 Charpy Notched Impact Strength (0 °C) 2 kJ/m2 ISO 179 - Thermal Properties
Value Units Test Method / Conditions Heat Deflection Temperature - HDT A (1.8 MPa) 47 °C ISO 75/A Heat Deflection Temperature - HDT B (0.45 MPa) 67 °C ISO 75/B Vicat Softening Point A (10 N) 127 °C ISO 306/B Vicat Softening Point B (50 N) 70 °C ISO 306/B - Optical Properties
Value Units Test Method / Conditions Clarity 85 % ASTM D1003
Regulatory & Compliance
- Certifications & Compliance
- Food Contact Compliance
Advance 400® Polypropylene Resin should comply with Commission Regulation (EU) No 10/2011 and with U.S. FDA 21 CFR 177.1520(c)3.2a food contact regulations when used unmodified and processed according to good manufacturing practices for food contact applications. The purchaser remains responsible for determining whether the use complies with all relevant regulations.